Vermillion announces publication of ovarian cancer symptoms index study
Vermillion announced the acceptance for publication of the original research titled, “Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy.” OVA1 (MIA) is now considered a Level B Recommendation by ACOG. March 29, 2017